{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:36:55Z","timestamp":1785908215132,"version":"3.56.0"},"reference-count":30,"publisher":"BMJ","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>B-type natriuretic peptide (BNP) is a marker for ventricular dysfunction secreted as a pre-prohormone, pro-B-type natriuretic peptide (proBNP), and cleaved into BNP and a biologically inactive fragment, N-terminal pro-B-type natriuretic peptide (NT-proBNP). Little is known about the clinical usefulness of NT-proBNP in preterm infants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>To evaluate the usefulness of plasma NT-proBNP in diagnosing haemodynamically significant patent ductus arteriosus (hsPDA) in neonates and examine some factors that might affect this.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Infants born at &lt;34 weeks\u2019 gestational age (GA) and &lt;2 kg birth weight (BW) were prospectively enrolled within 6\u201312 hours of birth. Plasma NT-proBNP levels were measured on days 1, 3, 5 and 10 with simultaneous echocardiography done to detect hsPDA and assess ventricular function. Significant PDA was diagnosed by large ductal flow with left to right shunt on colour Doppler, measuring &gt;1.6 mm on two-dimensional echocardiography, along with clinical features of PDA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Forty-nine infants were analysed. Median GA was 30 weeks (range 24\u201333) and median BW 1220 g (range 550\u20131950). Eighteen infants with hsPDA had higher day 3 plasma NT-proBNP values (median 32\u2009907 pg\/ml; range 11\u2009396\u2013127\u2009155) (p&lt;0.001) than controls (median 3147 pg\/ml; range 521\u201310\u2009343). Infants who developed sepsis had higher day 10 plasma NT-proBNP levels. Area under receiver operator characteristic curve for detection of hsPDA, by day 3 NT-proBNP value, was significant 0.978 (95% CI 0.930 to 1.026). NT-proBNP was predictive of hsPDA (sensitivity 100%; specificity 95%) at a cut-off value of 11\u2009395 pg\/ml.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Plasma NT-proBNP level on day 3 is a good marker for hsPDA in preterm infants. Serial measurements of NT-proBNP may be useful in assessing the clinical course of PDA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/adc.2007.120691","type":"journal-article","created":{"date-parts":[[2008,1,24]],"date-time":"2008-01-24T20:24:54Z","timestamp":1201206294000},"page":"F257-F260","source":"Crossref","is-referenced-by-count":60,"title":["N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus"],"prefix":"10.1136","volume":"93","author":[{"given":"I","family":"Farombi-Oghuvbu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P D","family":"Mayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2008,1,24]]},"reference":[{"key":"2025090509461597000_93.4.F257.1","unstructured":"Gorenjak M Natriuretic peptides in assessment of ventricular dysfunction. eJIFCC Vol 14 No 2. Available at http:\/\/www.ifcc.org\/ejifcc\/vol14no2\/1402062003011n.htm (accessed 19 February 2008)."},{"key":"2025090509461597000_93.4.F257.2","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.113215"},{"key":"2025090509461597000_93.4.F257.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020233"},{"key":"2025090509461597000_93.4.F257.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01156-6"},{"key":"2025090509461597000_93.4.F257.5","doi-asserted-by":"publisher","DOI":"10.1186\/cc2890"},{"key":"2025090509461597000_93.4.F257.6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-0525"},{"key":"2025090509461597000_93.4.F257.7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.6.e76"},{"key":"2025090509461597000_93.4.F257.8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/cs1030079","article-title":"Natriuretic peptides as markers of patent ductus arteriosus in preterm infants.","volume":"103","author":"Holstrom","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"2025090509461597000_93.4.F257.9","doi-asserted-by":"publisher","DOI":"10.1080\/08035250119367"},{"key":"2025090509461597000_93.4.F257.10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/cs1030075","article-title":"Plasma natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants.","volume":"103","author":"Puddy","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"2025090509461597000_93.4.F257.11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1837"},{"key":"2025090509461597000_93.4.F257.12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1542\/peds.90.6.899","article-title":"Persistent pulmonary hypertension in premature infants with severe respiratory distress syndrome.","volume":"90","author":"Walther","year":"1992","journal-title":"Pediatrics"},{"key":"2025090509461597000_93.4.F257.13","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.106569"},{"key":"2025090509461597000_93.4.F257.14","doi-asserted-by":"publisher","DOI":"10.1136\/adc.68.1_Spec_No.58"},{"key":"2025090509461597000_93.4.F257.15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1440-1754.1994.tb00689.x","article-title":"A blinded comparison of clinical and echochardiographic evaluation of the preterm infant for patent ductus arteriosus.","volume":"30","author":"Skelton","year":"1994","journal-title":"J Paediatr Child Health"},{"key":"2025090509461597000_93.4.F257.16","doi-asserted-by":"publisher","DOI":"10.1053\/siny.2000.0037"},{"key":"2025090509461597000_93.4.F257.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70239-8"},{"key":"2025090509461597000_93.4.F257.18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/fn.76.3.F179","article-title":"Treatment of patent ductus arteriosus with ibuprofen.","volume":"76","author":"Van Overmeire","year":"1997","journal-title":"Arch Dis Child"},{"key":"2025090509461597000_93.4.F257.19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0022-3476(05)83342-6","article-title":"Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus.","volume":"117","author":"Hammerman","year":"1990","journal-title":"J Pediatr"},{"key":"2025090509461597000_93.4.F257.20","doi-asserted-by":"publisher","DOI":"10.1136\/adc.67.10_Spec_No.1169"},{"key":"2025090509461597000_93.4.F257.21","doi-asserted-by":"crossref","unstructured":"Kluckow M Evans N Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch Dis Child Fetal Neonatal Ed 2000;82:F188\u201394.","DOI":"10.1136\/fn.82.3.F188"},{"key":"2025090509461597000_93.4.F257.22","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198704000-00015"},{"key":"2025090509461597000_93.4.F257.23","doi-asserted-by":"publisher","DOI":"10.1136\/adc.62.11.1165"},{"key":"2025090509461597000_93.4.F257.24","doi-asserted-by":"publisher","DOI":"10.1080\/080352501300049406"},{"key":"2025090509461597000_93.4.F257.25","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0569"},{"key":"2025090509461597000_93.4.F257.26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/147323000403200109","article-title":"Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes.","volume":"32","author":"Tanaka","year":"2004","journal-title":"J Int Med Res"},{"key":"2025090509461597000_93.4.F257.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1910-0"},{"key":"2025090509461597000_93.4.F257.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.472050"},{"key":"2025090509461597000_93.4.F257.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2004.01.001"},{"key":"2025090509461597000_93.4.F257.30","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00684.2005"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/adc.2007.120691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T16:46:32Z","timestamp":1757090792000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/adc.2007.120691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,24]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,6,20]]},"published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1136\/adc.2007.120691"],"URL":"https:\/\/doi.org\/10.1136\/adc.2007.120691","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,24]]}}}